How do you get that 30%? If Provenge produced a benefit across all Gleason scores--which it did in 9901, then on what basis do you worry that the sicker patients will skew the curve? Isn't it true that sicker or healthier for each class of patient the average survival advantage was 4.5 months?
News 
Market Data 
Discover 
AI
